Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Nanomedicine (London, England)|May 7, 2025
From conventional therapy to novel nano-based approaches. A focus on prostate cancerLorenzo Chiaverini, Giarita Ferraro, Riccardo Di Leo, et al.
Oncology Reports|January 14, 2004
Regulation of telomerase and its hTERT messenger in colorectal cancerLaura Boldrini, Pinuccia Faviana, Silvia Gisfredi, et al.
Scientific Reports|February 5, 2025
Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategyMatteo Pacini, Alessandro Zucchi, Riccardo Morganti, et al.
Oncogene|June 9, 2004
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomasMaria D Castellone, Valentina Guarino, Valentina De Falco, et al.
Nature Biomedical Engineering|June 26, 2025
Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapyTony Georgiev, Francesca Migliorini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry|May 16, 2026
A Small-Molecule Drug Conjugate Targeting FAP Exhibits Potent Activity in Dogs with Spontaneous TumorsAndrea Galbiati, Paola Roccabianca, Silvia Dell'Aere, et al.
Pharmacogenomics|May 7, 2014
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patientsMina Maftouh, Amir Avan, Niccola Funel, et al.
International Journal of Cancer|January 25, 2002
Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangementFulvio Basolo, Riccardo Giannini, Antonio Toniolo, et al.
Targeted Oncology|July 4, 2013
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecanFotios Loupakis, Chiara Cremolini, Anna Fioravanti, et al.
Hematological Oncology|March 16, 2026
UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific EngagerDaniele Caracciolo, Carlo Gentile, Sara Squillacioti, et al.
Pageof 7